Your browser is no longer supported. Please, upgrade your browser.
Applied Molecular Transport Inc.
Index- P/E- EPS (ttm)-2.08 Insider Own24.50% Shs Outstand35.22M Perf Week10.02%
Market Cap1.89B Forward P/E- EPS next Y-2.67 Insider Trans0.09% Shs Float29.06M Perf Month6.14%
Income-71.70M PEG- EPS next Q-0.60 Inst Own63.60% Short Float9.75% Perf Quarter-26.17%
Sales- P/S- EPS this Y-236.20% Inst Trans1.30% Short Ratio9.62 Perf Half Y56.83%
Book/sh3.22 P/B15.51 EPS next Y-4.70% ROA-48.00% Target Price75.75 Perf Year80.13%
Cash/sh2.86 P/C17.49 EPS next 5Y38.70% ROE-51.30% 52W Range20.02 - 78.22 Perf YTD62.33%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-42.79% Beta-
Dividend %- Quick Ratio12.60 Sales past 5Y- Gross Margin- 52W Low123.53% ATR3.62
Employees90 Current Ratio12.60 Sales Q/Q- Oper. Margin- RSI (14)45.07 Volatility7.86% 7.07%
OptionableYes Debt/Eq0.00 EPS Q/Q-23.00% Profit Margin- Rel Volume0.71 Prev Close49.95
ShortableYes LT Debt/Eq0.00 EarningsMay 13 AMC Payout- Avg Volume294.63K Price44.75
Recom1.20 SMA20-4.53% SMA50-4.65% SMA2009.58% Volume201,161 Change-10.41%
Mar-17-21Initiated JMP Securities Mkt Outperform $92
Jun-30-20Initiated SVB Leerink Outperform $32
Jun-30-20Initiated Jefferies Buy $38
Jun-30-20Initiated BofA Securities Buy $34
Jun-13-21 12:46PM  
Jun-09-21 08:00AM  
May-26-21 08:00AM  
May-13-21 04:01PM  
May-06-21 08:00AM  
Apr-27-21 03:17PM  
Apr-08-21 01:08AM  
Apr-06-21 04:01PM  
Mar-31-21 08:45PM  
Mar-29-21 04:11PM  
Mar-22-21 08:00AM  
Mar-19-21 04:05PM  
Mar-13-21 06:56AM  
Mar-09-21 08:00AM  
Mar-04-21 11:30PM  
Mar-01-21 08:00AM  
Feb-17-21 08:00AM  
Jan-19-21 08:00AM  
Dec-05-20 01:24AM  
Nov-24-20 08:00AM  
Nov-12-20 04:05PM  
Nov-11-20 08:00AM  
Nov-10-20 08:00AM  
Sep-22-20 08:00AM  
Sep-06-20 09:35AM  
Aug-27-20 08:00AM  
Aug-11-20 04:00PM  
Aug-05-20 08:00AM  
Jun-16-20 08:13AM  
Jun-09-20 04:05PM  
Jun-04-20 10:40PM  
Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company's lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trial for the treatment of ulcerative colitis and related inflammatory indications. It is also involved in developing AMT-126, a GI-selective oral fusion of interleukin 22, which is in a Phase Ia clinical trial for diseases related to intestinal epithelium barrier function defects. The company, through its technology platform, designs and develops various oral biologic therapeutic modalities, such as peptides, proteins, antibodies, antibody fragments, and ribonucleic acid therapeutics. Applied Molecular Transport Inc. was founded in 2010 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bhatt ElizabethChief Bus. & Strategy OfficerApr 21Option Exercise4.619,00041,4909,000Apr 22 06:29 PM
Bhatt ElizabethChief Bus. & Strategy OfficerApr 21Sale40.519,000364,5570Apr 22 06:29 PM
Kanwar BittooChief Medical OfficerApr 07Option Exercise2.387,50017,8507,500Apr 08 09:15 PM
Kanwar BittooChief Medical OfficerApr 07Sale54.797,500410,9460Apr 08 09:15 PM
Lamond DavidDirectorApr 06Buy42.0025,0001,050,0001,011,019Apr 07 06:47 PM
Kim Helen SusanDirectorJul 02Option Exercise0.02800,00016,000800,000Jul 06 05:41 PM